Loading…
Reported covered position: Sr. Legis. Asst., Rep. Newhouse; Legis. Asst., Aug., Rep. Newhouse; Legis. Asst./Press Asst., Rep. Stefanik; Intern, Rep. Stefanik.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Fairness for Rape Kit Backlog Survivors Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2026 · third_quarter · Q3
S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; Drug pricing and reimbursement issues; Vaccine issues; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property and trade issues; International competition in biopharmaceuticals.
Source: Senate LDA
Fairness for Rape Kit Backlog Survivors Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; Drug pricing and reimbursement issues; Vaccine issues; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property and trade issues; International competition in biopharmaceuticals.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Issues relating to, S. 1163, Rural Veterinary Workforce Act Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Farm, Food, and National Security Act of 2024
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 8467, Farm, Food, and National Security Act of 2024 Issues relating to, United Stated Department of Agriculture; Animal and Plant Health Inspection Service; Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024)
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Prescription Information Modernization Act of 2023
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
Fairness for Rape Kit Backlog Survivors Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
Fairness for Rape Kit Backlog Survivors Act of 2021
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Issues relating to, Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026; United States Department of Agriculture, Animal and Plant Health Inspection Service, Final Rule: Use of Electronic Identification Ear tags as Official Identification in Cattle and Bison.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2026 · second_quarter · Q2
Issues relating to, Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2026 · first_quarter · Q1
Issues relating to, Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Bill, 2026; Commerce, Justice, Science, and Related Agencies Appropriations Bill, 2026; Interior, Environment, and Related Agencies Appropriations Bill 2026.
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing; Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients; International competition in biopharmaceuticals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2025 · fourth_quarter · Q4
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
Issues relating to, Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2025 · second_quarter · 2A
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
Issues relating to, Agriculture; Animal Health; Animal Health Technology; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; United States Department of Agriculture, Animal and Plant Health Inspection Service, Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024).
Filing targets: Bureau of Industry and Security (BIS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MERCK & CO INC via MERCK & CO, INC.
2025 · third_quarter · Q3
H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
MERCK & CO INC via MERCK & CO, INC.
2025 · second_quarter · Q2
H.R. 1, One Big Beautiful Bill, issues related to health care H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, (Docket No. 250411-0065).
MERCK & CO INC via MERCK & CO, INC.
2025 · first_quarter · Q1
H.R. 1244, Reducing Drug Prices for Seniors Act H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 S. 1040, Drug Competition Enhancement Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2076 Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Prescription drug cost-sharing; Anti-microbial Resistance; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines issues; Vaccine misinformation; Measles, Mumps, and Rubella (MMR) immunizations; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2025 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO IP Waiver for COVID therapeutics; Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; One Health Issues; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues.
Issues relating to, S. 1163, Rural Veterinary Workforce Act Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Issues relating to, Agriculture; Animal Health; Animal Health Technology; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; United States Department of Agriculture, Animal and Plant Health Inspection Service, Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024).
Filing targets: Bureau of Industry and Security (BIS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 8467, Farm, Food, and National Security Act of 2024 Issues relating to, United Stated Department of Agriculture; Animal and Plant Health Inspection Service; Final Rule regarding use of electronic identification eartags as official identification in cattle and bison (89 Fed. Reg. 39,541-39,566, May 9, 2024)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE